Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer
View/ Open
Author
Kamat, Ashish M.
Lerner, Seth
Black, Peter
Dinney, Colin
Hahn, Noah M.
O’Donnell, Michael
Quale, Diane Z.
Published Version
https://doi.org/10.3233/BLC-170118Metadata
Show full item recordCitation
Kamat, Ashish M., Seth Lerner, Peter Black, Joaquim Bellmunt, Colin Dinney, Noah M. Hahn, Michael O’Donnell, and Diane Z. Quale. 2017. “Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.” Bladder Cancer (Amsterdam, Netherlands) 3 (3): 145-146. doi:10.3233/BLC-170118. http://dx.doi.org/10.3233/BLC-170118.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545902/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34375110
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)